Needham analyst Alan Carr raised his price target on Biohaven Pharmaceutical to $70 and kept his Buy rating after its Q1 results and updated progress on its glutamate modulating platform. The analyst anticipates approval of the company’s Nurtec for ALS by July 2019 PDUFA date with $24M in peak sales modeled for the program and also cites migraine platform expansion with the start of Phase 2/3 trial of intranasal BHV-3500 in Acute Migraine in April.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.